The Canadian Competition Bureau does not consider life-cycle management strategies to be inherently anti-competitive (Alcon)

Introduction The Competition Bureau (the Bureau), Canada’s competition watchdog, announced in May 2014 that it was dropping its investigation into the life cycle management strategy used by Alcon Canada Inc. (Alcon) in connection with its Patanol and Pataday products. The Bureau commenced an inquiry in November 2012 to examine whether Alcon was dominant in a relevant market and if so, 'whether it had intentionally disrupted the supply of its prescription ocular anti-allergy drug, Patanol, as part of a strategy to switch patients to a second generation formula of the drug and hinder meaningful competition from generic drug companies' [1]. After a thorough review, the Bureau ended its investigation upon concluding that the competitive dynamic had returned in the market and that Alcon’s

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Canadian Competition Tribunal
  • Norton Rose Fulbright (Toronto)
  • Norton Rose Fulbright (Ottawa)

Quotation

Denis Gascon, Kevin Ackhurst, Richard A. Wagner, The Canadian Competition Bureau does not consider life-cycle management strategies to be inherently anti-competitive (Alcon), 13 May 2014, e-Competitions Bulletin May 2014, Art. N° 72318

Visites 70

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues